Cargando…
Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?
According to the WHO, as of January 2023, more than 850 million cases and over 6.6 million deaths from COVID-19 have been reported worldwide. Currently, the death rate has been reduced due to the decreased pathogenicity of new SARS-CoV-2 variants, but the major factor in the reduced death rates is t...
Autores principales: | Hromić-Jahjefendić, Altijana, Barh, Debmalya, Uversky, Vladimir, Aljabali, Alaa A., Tambuwala, Murtaza M., Alzahrani, Khalid J., Alzahrani, Fuad M., Alshammeri, Saleh, Lundstrom, Kenneth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960675/ https://www.ncbi.nlm.nih.gov/pubmed/36851087 http://dx.doi.org/10.3390/vaccines11020208 |
Ejemplares similares
-
COVID-19 Vaccines and Myocarditis: An Overview of Current Evidence
por: Hromić-Jahjefendić, Altijana, et al.
Publicado: (2023) -
COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity
por: Lundstrom, Kenneth, et al.
Publicado: (2023) -
Associations and Disease–Disease Interactions of COVID-19 with Congenital and Genetic Disorders: A Comprehensive Review
por: Hromić-Jahjefendić, Altijana, et al.
Publicado: (2022) -
Viral Vector-Based Melanoma Gene Therapy
por: Hromic-Jahjefendic, Altijana, et al.
Publicado: (2020) -
COVID-19 signalome: Potential therapeutic interventions
por: Lundstrom, Kenneth, et al.
Publicado: (2023)